1. Home
  2. OZ vs IPHA Comparison

OZ vs IPHA Comparison

Compare OZ & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belpointe PREP LLC Units

OZ

Belpointe PREP LLC Units

HOLD

Current Price

$46.14

Market Cap

184.9M

Sector

N/A

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.75

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OZ
IPHA
Founded
2020
1999
Country
United States
France
Employees
N/A
163
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
184.9M
189.5M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
OZ
IPHA
Price
$46.14
$1.75
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
7.9K
16.4K
Earning Date
05-19-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,187,000.00
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
243.44
N/A
52 Week Low
$45.78
$1.18
52 Week High
$69.00
$2.63

Technical Indicators

Market Signals
Indicator
OZ
IPHA
Relative Strength Index (RSI) 42.62 53.70
Support Level N/A $1.73
Resistance Level $48.50 $1.90
Average True Range (ATR) 0.81 0.07
MACD 0.06 -0.01
Stochastic Oscillator 39.34 55.59

Price Performance

Historical Comparison
OZ
IPHA

About OZ Belpointe PREP LLC Units

Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: